Margareth C Ozelo

List of Publications by Year
in descending order

110 papers	5,434 citations	186209 28 h-index	85498 71 g-index
111 all docs	111 docs citations	111 times ranked	4352 citing authors

#	Article	IF	Citations
1	Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature. Blood Advances, 2022, 6, 228-237.	2.5	15
2	International consensus recommendations on the management of people with haemophilia B. Therapeutic Advances in Hematology, 2022, 13, 204062072210852.	1.1	13
3	Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. New England Journal of Medicine, 2022, 386, 1013-1025.	13.9	157
4	Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A. Human Gene Therapy, 2022, 33, 432-441.	1.4	37
5	Impact of novel hemophilia therapies around the world. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12695.	1.0	19
6	First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood, 2022, 139, 3699-3707.	0.6	13
7	Haemophilia gene therapyâ€"Update on new country initiatives. Haemophilia, 2022, 28, 61-67.	1.0	8
8	ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Advances, 2021, 5, 301-325.	2.5	152
9	Knee radiosynovectomy with 153Sm-hydroxyapatite compared to 90Y-hydroxyapatite: initial results of a prospective trial. Annals of Nuclear Medicine, 2021, 35, 232-240.	1.2	3
10	Aquatic exercise in patients with haemophilia: Electromyographic and functional results from a prospective cohort study. Haemophilia, 2021, 27, e221-e229.	1.0	2
11	Addressing unmet needs in rare bleeding disorders: selected poster extracts of recent research in hemophilia A and von Willebrand disease presented at the 14th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (Feb 3â€"5, 2021; virtual congress). Expert Review of Hematology, 2021, 14, 1-18.	1.0	2
12	Acquired Hemophilia a Relapse Is Related to Th2 Response, and Increased Expression of B-Cell Activating Factor (BAFF). Blood, 2021, 138, 497-497.	0.6	1
13	Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial. Blood, 2021, 138, 3972-3972.	0.6	0
14	Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study. Journal of Clinical Medicine, 2021, 10, 5959.	1.0	9
15	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	1.0	32
16	Longâ€term safety and sustained efficacy for up to 5Âyears of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the Bâ€¥OND extension study. Haemophilia, 2020, 26, e262-e271.	1.0	28
17	Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B. Molecular Therapy, 2020, 28, 2073-2082.	3.7	123
18	Haemophilia Experiences, Results and Opportunities (HERO study) in Brazil: Assessment of the psychosocial effects of haemophilia in patients and caregivers. Haemophilia, 2019, 25, 640-650.	1.0	9

#	Article	IF	Citations
19	Longitudinal sequencing of <scp>RUNX</scp>1 familial platelet disorder: new insights into genetic mechanisms of transformation to myeloid malignancies. British Journal of Haematology, 2019, 186, 724-734.	1.2	9
20	Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 427-438.	0.8	8
21	Gene Therapy: Paving New Roads in the Treatment of Hemophilia. Seminars in Thrombosis and Hemostasis, 2019, 45, 743-750.	1.5	13
22	Impact of prophylaxis on healthâ€related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 397-404.	1.0	12
23	The 1st <scp>WFH</scp> Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world. Haemophilia, 2019, 25, 189-194.	1.0	31
24	Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 109-113.	1.0	8
25	Guideline on immune thrombocytopenia in adults: AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Project guidelines: AssociaÃ§Ã£o MÃ©dica Brasileira â€“ 2018. Hematology, Transfusion and Cell Therapy, 2018, 40, 50-74.	0.1	18
26	Longâ€term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial. Haemophilia, 2018, 24, e391-e394.	1.0	15
27	Obesity in the global haemophilia population: prevalence, implications and expert opinions for weight management. Obesity Reviews, 2018, 19, 1569-1584.	3.1	34
28	Haemophilia care in Latin America: Assessment and perspectives. Haemophilia, 2018, 24, e395-e401.	1.0	10
29	Vinorelbine-Based Hematopoietic Stem-Cell Mobilization: A More Effective, Low-Cost Alternative to Conventional Chemotherapy. Blood, 2018, 132, 4762-4762.	0.6	0
30	Creating a Population Model for PK-Tailored Dosing Using Real-World Data from the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Platform. Blood, 2018, 132, 1191-1191.	0.6	0
31	Endothelial Colony-Forming Cells (ECFC) As an Autologous Model for Studying Endothelial Pathophysiology in Sickle Cell Anemia and Myeloproliferative Neoplasms. Blood, 2018, 132, 74-74.	0.6	0
32	Proliferative Sickle Cell Retinopathy in SS and SC Hemoglobinopathies: Identification of New Candidate Genes. Blood, 2018, 132, 2368-2368.	0.6	0
33	Incidence of Inhibitors in a Previously Untreated Patients with Severe Hemophilia Î‘ Cohort Treated with a Single Third-Generation Recombinant Factor VIII Concentrate. Blood, 2018, 132, 1211-1211.	0.6	2
34	Comparing the burden of illness of haemophilia between resourceâ€constrained and unconstrained countries: the SÃ£o Pauloâ€“Toronto Hemophilia Study. Haemophilia, 2017, 23, 682-688.	1.0	19
35	Zika virus and inherited bleeding disorders. Haemophilia, 2017, 23, 177-179.	1.0	1
36	Evaluation of the immature platelet fraction contribute to the differential diagnosis of hereditary, immune and other acquired thrombocytopenias. Scientific Reports, 2017, 7, 3355.	1.6	35

#	Article	IF	Citations
37	Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thrombosis and Haemostasis, 2017, 117, 508-518.	1.8	31
38	Thalidomide for the Treatment of Gastrointestinal Bleeding Due to Angiodysplasia in a Patient with Glanzmannâ€™s Thrombasthenia. Hematology Reports, 2017, 9, 6961.	0.3	8
39	Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage â€“ the <scp>MUSFIH</scp> study. Haemophilia, 2017, 23, 538-546.	1.0	20
40	The utility of International Society on Thrombosis and Haemostasis-Bleeding Assessment Tool and other bleeding questionnaires in assessing the bleeding phenotype in two platelet function defects. Blood Coagulation and Fibrinolysis, 2016, 27, 589-593.	0.5	20
41	Validity of the Portuguese CHOâ€KLAT in Brazil. Haemophilia, 2016, 22, 894-897.	1.0	6
42	When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 1105-1109.	1.9	54
43	Clinical Outcomes in Adults/Adolescents with Hemophilia B Treated Long Term with Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis: Interim Results of the B-Yond Extension Study. Blood, 2016, 128, 1416-1416.	0.6	1
44	Safety and Efficacy of Turoctocog Alfa in Prevention and on-Demand Treatment of Bleeding Episodes in Patients with Hemophilia A. Blood, 2016, 128, 3790-3790.	0.6	0
45	Updates from guardian^{â„¢}: a comprehensive registration programme. European Journal of Haematology, 2015, 95, 22-29.	1.1	0
46	Impact of severe haemophilia A on patients' health status: results from the guardian^{â„¢} 1 clinical trial of turoctocog alfa (NovoEight^{Â®}). Haemophilia, 2015, 21, 451-457.	1.0	8
47	Longâ€term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight^{Â®}) in previously treated patients with severe haemophilia A: interim results of the guardian^{â„¢}2 extension trial. Haemophilia, 2015, 21, e436-9.	1.0	10
48	Allergic reaction in a cohort of haemophilia A patients using plasmaâ€derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII. Haemophilia, 2015, 21, e281-5.	1.0	7
49	Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15033.	1.8	2
50	Heat treatment of samples improve the performance of the Nijmegenâ€“Bethesda assay in hemophilia A patients undergoing immune tolerance induction. Thrombosis Research, 2015, 136, 1280-1284.	0.8	14
51	Longâ€acting recombinant factor IX Fc fusion protein (<scp>rFIXF</scp>c) for perioperative management of subjects with haemophilia B in the phase 3 <scp>Bâ€LONG</scp> study. British Journal of Haematology, 2015, 168, 124-134.	1.2	45
52	Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors. Blood Reviews, 2015, 29, S9-S18.	2.8	21
53	A longitudinal evaluation of antiâ€<scp>FVIII</scp> antibodies demonstrated IgG4 subclass is mainly correlated with highâ€titre inhibitor in haemophilia A patients. Haemophilia, 2015, 21, 686-692.	1.0	27
54	Switching to recombinant factor <scp>IX</scp> Fc fusion protein prophylaxis results in fewer infusions, decreased factor <scp>IX</scp> consumption and lower bleeding rates. British Journal of Haematology, 2015, 168, 113-123.	1.2	31

#	Article	IF	Citations
55	Differential Diagnosis of Hereditary and Acquired Thrombocytopenia By the Immature Platelet Fraction and Thrombopoietin Levels. Blood, 2015, 126, 1049-1049.	0.6	2
56	Musculoskeletal evaluation in severe haemophilia A patients from Latin America. Haemophilia, 2014, 20, e63-70.	1.0	7
57	Safety and efficacy of cryoprecipitateâ€poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: A single center retrospective evaluation. Journal of Clinical Apheresis, 2014, 29, 311-315.	0.7	22
58	Systematic Analysis of Bleeding Phenotype in PT-VWD Compared to Type 2B VWD Using an Electronic Bleeding Questionnaire. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 765-771.	0.7	12
59	Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response. Blood, 2014, 123, 4045-4053.	0.6	28
60	Impact of Two Immobilized GPIbÎ± Assays in the Diagnosis of Von Willebrand Disease. Blood, 2014, 124, 1524-1524.	0.6	0
61	Results from a large multinational clinical trial (guardianâ„¢3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia <scp>A</scp>: safety, efficacy and pharmacokinetics. Haemophilia, 2013, 19, 698-705.	1.0	59
62	Results from a large multinational clinical trial (guardianâ„¢1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia <scp>A</scp>: safety and efficacy. Haemophilia, 2013, 19, 691-697.	1.0	81
63	Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B. New England Journal of Medicine, 2013, 369, 2313-2323.	13.9	307
64	Increased adhesive and inflammatory properties in blood outgrowth endothelial cells from sickle cell anemia patients. Microvascular Research, 2013, 90, 173-179.	1.1	27
65	A novel use of thromboelastography in type 2B von Willebrand disease. International Journal of Laboratory Hematology, 2013, 35, e11-4.	0.7	5
66	Establishing a harmonized haemophilia registry for countries with developing health care systems. Haemophilia, 2013, 19, 668-673.	1.0	6
67	Factor <scp>VIII</scp> inhibitors in patients with congenital severe haemophilia <scp>A</scp> and its relation to genotype. Haemophilia, 2012, 18, e411-4.	1.0	1
68	Surgery in patients with hemophilia: Is thromboprophylaxis mandatory?. Thrombosis Research, 2012, 130, S23-S26.	0.8	23
69	Nonâ€operative management of blunt major hepatic injury in a young adult with severe haemophilia A. Haemophilia, 2012, 18, e84-6.	1.0	3
70	Meeting the challenges of haemophilia care and patient support in China and Brazil. Haemophilia, 2012, 18, 33-38.	1.0	23
71	Thrombotic Thrombocytopenic Purpura Triggered by Inflammatory Pseudotumor: A Report of a Rare Case. Blood, 2012, 120, 4660-4660.	0.6	0
72	Greater Need for FVIII Replacement in Patients of Type Non-O Blood Groups with Moderate Hemophilia A. Blood, 2012, 120, 4390-4390.	0.6	0

#	Article	IF	Citations
73	Frequency of Platelet type versus Type 2B von Willebrand Disease. Thrombosis and Haemostasis, 2011, 105, 501-508.	1.8	52
74	Evaluation of the host response to endotoxemia of FVIII and FIX deficient mice. Haemophilia, 2011, 17, 800-807.	1.0	4
75	A MicroRNA-regulated and GP64-pseudotyped Lentiviral Vector Mediates Stable Expression of FVIII in a Murine Model of Hemophilia A. Molecular Therapy, 2011, 19, 723-730.	3.7	72
76	Adhesive and Inflammatory Properties Are Increased in Blood Outgrowth Endothelial Cells From Patients with Sickle Cell Anemia. Blood, 2011, 118, 2133-2133.	0.6	0
77	Six Novel Mutations Identified in the Glycoproteins Ib Alpha, Ib Beta and IX Genes Among Twenty-Two Unrelated Patients with Bernard-Soulier Syndrome in Brazil. Blood, 2011, 118, 1156-1156.	0.6	0
78	Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood, 2010, 116, 5842-5848.	0.6	144
79	Unique strategies for therapeutic gene transfer in haemophilia A and haemophilia B. WFH Stateâ€ofâ€theâ€Art Session on Therapeutic Gene Transfer Buenos Aires, Argentina. Haemophilia, 2010, 16, 29-34.	1.0	37
80	Long-term prospective study of recurrent venous thromboembolism in a Hispanic population. Blood Coagulation and Fibrinolysis, 2010, 21, 660-665.	0.5	8
81	VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. Thrombosis Research, 2010, 126, e206-e210.	0.8	14
82	Simultaneous bleeding and thrombosis in superwarfarin poisoning. Thrombosis Research, 2009, 123, 637-639.	0.8	13
83	Assessing the Coagulation Factor Levels, Inherited Thrombophilia, and ABO Blood Group on the Risk for Venous Thrombosis Among Brazilians. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 408-414.	0.7	23
84	Genetically-Engineered Endothelial Cells Implanted Into the Omentum of Hemophilia A Dogs Provides Long-Term Circulating FVIII Resulting From Sustained FVIII Expression and Persistent Cell Viability.. Blood, 2009, 114, 3578-3578.	0.6	13
85	Inhibitors of factor VIII in hemophilia. New England Journal of Medicine, 2009, 361, 309-10; author reply 310.	13.9	8
86	Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk. Leukemia Research, 2008, 32, 401-405.	0.4	32
87	Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells. Journal of Thrombosis and Haemostasis, 2008, 6, 2095-2104.	1.9	36
88	Low density lipoprotein receptor-related protein polymorphisms are not risk factors for venous thromboembolism. Thrombosis Research, 2008, 121, 625-629.	0.8	14
89	Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Platelets, 2008, 19, 489-495.	1.1	46
90	Molecular Genetic Testing of Hemostasis and Thrombosis in Developing Countries: Achievements, Hopes, and Challenges. Seminars in Thrombosis and Hemostasis, 2008, 34, 569-578.	1.5	1

#	Article	IF	Citations
91	Association between estrogen receptor alpha and beta gene polymorphisms and deep vein thrombosis. Thrombosis Research, 2007, 120, 639-645.	0.8	26
92	A cost evaluation of treatment alternatives for mildâ€toâ€moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil. Haemophilia, 2007, 13, 462-469.	1.0	27
93	Evidence of Multiyear Factor IX Expression by AAV-Mediated Gene Transfer to Skeletal Muscle in an Individual with Severe Hemophilia B. Molecular Therapy, 2006, 14, 452-455.	3.7	196
94	Early in vivo anticoagulation inhibits the angiogenic response following hindlimb ischemia in a rodent model. Thrombosis and Haemostasis, 2006, 96, 68-72.	1.8	5
95	An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nature Genetics, 2006, 38, 807-812.	9.4	172
96	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine, 2006, 12, 342-347.	15.2	1,865
97	Clinical Impact of Oral Health Indexes in Dental Extraction of Hemophilic Patients. Journal of Oral and Maxillofacial Surgery, 2006, 64, 785-788.	0.5	12
98	Efficacy, Safety and Economic Evaluation of Recombinant Activated Factor VII (rFVIIa) in the Management of Mild and Moderate Bleedings in Haemophilia Patients with Inhibitors in Brazil.. Blood, 2006, 108, 4062-4062.	0.6	0
99	Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernardâ€“Soulier syndrome. Annals of Hematology, 2005, 84, 816-822.	0.8	43
100	Platelet glycoprotein IbÎ± polymorphisms modulate the risk for myocardial infarction. Thrombosis and Haemostasis, 2004, 92, 384-386.	1.8	14
101	1002. Immune Responses to AAV and to Factor IX in a Phase I Study of AAV-Mediated, Liver-Directed Gene Transfer for Hemophilia B. Molecular Therapy, 2004, 9, S383-S384.	3.7	12
102	Genetic variability of platelet glycoprotein IbÎ± gene. American Journal of Hematology, 2004, 77, 107-116.	2.0	6
103	Effects of high platelet concentration in collecting and freezing dry platelets concentrates. Transfusion and Apheresis Science, 2004, 30, 205-212.	0.5	12
104	Inherited Mutation in Exon 2 of GATA-1 Is Associated with a Clinical and Laboratory Picture Similar to Familial Hypocellular Myelodysplastic Syndrome (MDS).. Blood, 2004, 104, 3432-3432.	0.6	1
105	Rapid detection of the prothrombin C20209T variant by differential sensitivity to restriction endonuclease digestion. Journal of Thrombosis and Haemostasis, 2003, 1, 2683-2685.	1.9	3
106	AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 2003, 101, 2963-2972.	0.6	707
107	The impact of the search for thrombophilia risk factors among antiphospholipid syndrome patients with thrombosis. Blood Coagulation and Fibrinolysis, 2000, 11, 679-682.	0.5	19
108	Possible Association between Cytomegalovirus Infection and Gastrointestinal Bleeding in Hemophiliac Patients. Acta Haematologica, 2000, 103, 73-77.	0.7	8

#	Article	IF	Citations
109	Title is missing!. Journal of Pediatric Orthopaedics, 1999, 19, 84-87.	0.6	30
110	Recent advances in therapeutic options for rare hemostatic disorders: selected poster extracts of recent research in hemophilia A, congenital hemophilia with inhibitors, von Willebrand disease, and thrombotic thrombocytopenic purpura presented at the 29th congress of the International Society on Thrombosis and Haemostasis (ISTH 2021, Jul 17â€“21; virtual congress). Expert Review of Hematology, 0, , 1-18.	1.0	0